About Us

Huw has over 30 years’ experience of leadership roles in public and private R&D-based companies within the biotechnology and pharmaceutical sector, with a particular focus on preclinical and clinical drug development, dilutive and non-dilutive financing and business development. Most recently he was a Non-executive Director of Ixaka Ltd and Chairman of Chronos Therapeutics Ltd. Huw is a non-executive Director of biotech industry body OBN. Huw holds a PhD in pharmacology from the University of Birmingham, UK.

Toni has over 20 years’ experience in business development and senior finance roles in both public and private companies, working in mature and emerging markets particularly in Europe and the USA where he has accomplished successful fundraises, transactions and fiscal management in the sector. He was previously CFO at Faron Pharmaceuticals Ltd., an AIM and Nasdaq First North listed clinical stage biopharmaceutical company based in the Finland and the US developing novel treatments for medical conditions with significant unmet needs. Toni has an MBA from the Helsinki School of Economics (currently Aalto University).

Helen has over 20 years’ experience in life sciences beginning her career as a research scientist at Cambridge Antibody Technology and Domantis, before transitioning into strategy and business development roles. She has been an active proponent of the UK biotech innovation ecosystem, leading the creation and delivery of the £180m Biomedical Catalyst competitive grant scheme, whilst at Innovate UK. In addition to her role in TheraCryf she is an Operating Advisor with SymBiosis Capital Management, a US based healthcare focused venture fund, and an independent board member of the University Commercialization Executive Board at the University of Bath. Helen holds a PhD in physiology and pharmacology from the University of Leicester, UK.

Glen has over 25 years’ experience in oncology drug development and has specialised in the translational medicine aspects of this process. He has successfully provided strategic and operational leadership from Phase I through to regulatory submissions and commercialisation. Glen is an Honorary Professor of Translational Medicine at the University of Sheffield and an MSc Module Tutor and Honorary Lecturer in Translational Science at the University of Manchester. He has an MB BS from the Royal Free Hospital School of Medicine in London, holds an MD from the University of Sheffield and is a Fellow of the Faculty of Pharmaceutical Medicine.

Susan’s background is in science, drug development with a particular focus in oncology, licensing, new company creation and venture capital. She has more than 20 years’ experience in non-executive roles in both public and private healthcare biotech. Currently Susan is Executive Chair of QBiotics Group Ltd and an NED on the board of Laverock Therapeutics Ltd. She is a member of the Investment Committee of CD3, the joint drug discovery initiative between the University of Leuven & the European Investment Fund (EIF), and a Trustee of the Roslin Foundation. Susan was previously Senior Independent Director & Chair of the Remuneration Committee at Vectura plc, NED and Chair of the Remuneration Committee of BTG plc (through to their acquisition by Boston Scientific]. She studied biochemistry at the University of Oxford, obtaining an MA and a DPhil.

Alan is a Venture Partner at Delin Ventures and is the former chief medical officer of Singapore-based ASLAN Pharmaceuticals PTE. Up until 2011, he was vice-president and head of oncology & infection at AstraZeneca, a role in which he was responsible for the overall strategy in oncology and infection from drug discovery to proof-of-concept. He was also chairman of AstraZeneca’s Therapy Area Portfolio Team and accountable for the design and delivery of all projects, including budgetary oversight. Prior to his career at AstraZeneca, Alan was European and global medical director for Amgen Inc.